Ferring, Blackstone Ink $570M Bladder Cancer Therapy Deal
Blackstone Life Sciences and Ferring Pharmaceuticals on Monday announced that they teamed up to invest $570 million into a new Ferring subsidiary devoted to an experimental bladder cancer therapy....To view the full article, register now.
Already a subscriber? Click here to view full article